James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Biotech Stocks: Is It Safe to Come out Now? (IBB, XBI)

Biotech stocks are getting smashed this week, but betting against the sector remains a bad idea. The only trick is getting the timing right.

Why Mosaic Co (MOS), ConAgra Foods Inc. (CAG) and Petroleo Brasileiro SA (PBR) Are 3 of Today’s Worst Stocks

Mosaic (MOS), ConAgra Foods (CAG) and Petroleo Brasileiro (PBR) couldn't win for losing on Tuesday. Here's what investors need to know.

Is the Post-Earnings Plunge an Opportunity to Buy CCL Stock?

CCL stock has been roughed up after a disappointing Q4 outlook from Carnival, but you may want to take a closer look at the bigger picture.

4 Things That Could Prevent the S&P 500 From Reaching 2,100

The S&P 500 may well reach the 2015 target Goldman Sachs set for it today. If it does though, it's going to take a miracle and a whole lot of blind investors.

Why Alibaba Group Holding Ltd (BABA), Merck & Co., Inc. (MRK) and BioMarin Pharmaceutical Inc. (BMRN) Are 3 of Today’s Worst Stocks

Monday proved to be less-than-compelling for owners of Alibaba Group (BABA), Merck (MRK) and BioMarin Pharmaceutical (BMRN).

Weatherford’s Plunge Finally Offers a Reason to Buy WFT Stock

WFT shares been battered and bruised by news of a highly dilutive offering, but this may truly be as bad as it can get for Weatherford.

Why La Quinta Holdings Inc (LQ), Freeport-McMoRan Inc (FCX) and Vertex Pharmaceuticals Incorporated (VRTX) Are 3 of Today’s Worst Stocks

La Quinta Holdings (LQ), Freeport-McMoRan (FCX) and Vertex Pharmaceuticals (VRTX) would love to have a do-over of today's session.

Target Stock: Can Nine Employees Affect an Entire Company? (TGT)

It seems irrelevant on the surface, since CVS Health is buying the business anyway, but owners of Target stock need to look at the bigger picture of the unionization of a particular store's pharmacy.

Biogen: BIIB Stock May Be a Rare Biotech Value

Rather than dwelling on the negatives of BIIB stock, it's time to start accentuating Biogen's positives -- like promising trials and a large pipeline.

Why Petroleo Brasileiro SA – Petrobras (ADR) (PBR), Verizon Communications Inc. (VZ) and Oracle Corporation (ORCL) Are 3 of Today’s Worst Stocks

Interest rate D-Day was particularly forgettable for owners of Petroleo Brasileiro (PBR), Verizon Communications (VZ) and Oracle (ORCL).